Re: Farmas USA
NVAX. El VIERNES ES FIESTA EN USA.
El proximo finde tenemos un encuentro importante para sector vacunas 16 th World Vaccine Congress taking place in Washington D.C. on March 29-31…
Louis Fries will be presenting on RSV for NVAX…
Speaker: NVAX’s Louis Fries
The RSV nanoparticle vaccine, progress towards infant and elder protection.
• Finding the path to developing a successful human RSV vaccine
• How this vaccine will reduce the consequences of disease caused by RSV in children, adults and pregnant women.
Partial Bio.;
‘Dr. Fries, who joined the Novavax team in 2011, has 22 years of experience in the clinical testing and development of human vaccines in academic, small biotech, and major biopharmaceutical environments. While a major career focus has been influenza, he has also had extensive involvement with bacterial and parasitic vaccines and therapeutic and prophylactic immunoglobulins. He has been an author of over 60 peer-reviewed publications. Most recently, following the acquisition of ID Biomedical by GSK Biologicals, Dr. Fries served as Director of Clinical Development from 2005 to 2011. He had previously served as Vice President of Clinical and Regulatory Affairs for Intellivax and ID Biomedical GSK Biologicals.’
